Hyperreactive Malarial Splenomegaly Syndrome--Can the Diagnostic Criteria Be Improved? by McGregor, Alastair et al.
Am. J. Trop. Med. Hyg., 93(3), 2015, pp. 573–576
doi:10.4269/ajtmh.14-0234
Copyright © 2015 by The American Society of Tropical Medicine and Hygiene
Hyperreactive Malarial Splenomegaly Syndrome—Can the Diagnostic Criteria Be Improved?
Alastair McGregor,* Tom Doherty, Patricia Lowe, Peter Chiodini, and William Newsholme
Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust, London, United Kingdom;
Guy’s and St. Thomas’ Hospital NHS Foundation Trust, London, United Kingdom; Malaria Reference Laboratory,
London School of Hygiene and Tropical Medicine, London, United Kingdom
Abstract. Hyperreactive Malarial Splenomegaly Syndrome (HMSS) was described and defined before sensitive tests
for malaria were available. We present a series of seven individuals who were referred to our clinics with possible HMSS.
Chronic malaria was demonstrated in those successfully treated but not in those who failed to respond to therapy. This
observation suggests that the newer molecular malaria assays have a role to play in the identification of individuals who
are likely to respond to treatment for HMSS in non-endemic regions.
INTRODUCTION
Hyperreactive malarial splenomegaly syndrome (HMSS),
previously tropical splenomegaly syndrome, is a poorly under-
stood condition thought to represent an exaggerated immune
response to recurrent or persistent malarial infection.1 HMSS
is characterized by a polyclonal hypergammaglobulinemia and
raised immunoglobulin M (IgM). Malarial infection stimulates
the transient production of lymphocytotoxic IgM antibodies
specific for activated CD8+ lymphocytes.2 In HMSS, these
antibodies persist, leading to an imbalance between CD4+ and
CD8+ T cells, and associated with nonspecific B-cell activa-
tion.3 IgM aggregates are phagocytosed by the cells of the
reticuloendothelial system, stimulating macrophage and T-cell
hyperplasia and eventually resulting in massive hypertrophy
of these tissues.4
Published criteria for the diagnosis of HMSS are based on
1) the exclusion of other causes of splenomegaly; 2) immu-
nity to malaria, defined as a strongly positive antibody test;
3) splenomegaly of at least 10 cm; 4) a serum concentration
of IgM at least two standard deviations above normal; and
5) a clinical and immunological response to malaria prophy-
laxis.1 An additional criterion 6) was suggested in 1997: evi-
dence of polyclonal nature of circulating lymphocytes (to
distinguish from hematological malignancy).5 The optimal
management of HMSS in non-endemic settings and the role
of malaria polymerase chain reaction (PCR) remain unclear.
In the below section Cases and in Table 1, we summarize
seven cases of “tropical splenomegaly” which were managed
in our clinics since 2003.
CASES
Case 1. A 22-year-old pregnant woman from Sierra Leone
was admitted to hospital with shortness of breath and
fatigue. She had migrated to the United Kingdom 4 years
before. Physical examination revealed gross splenomegaly.
On two occasions, blood film microscopy showed only anemia.
However, a solitary trophozoite of Plasmodium falciparum
was noted on a third film, performed 1 month after her initial
presentation. Subsequent testing revealed a raised serum total
IgM and strongly positive malaria serology.
She was treated with a 3-day course of oral quinine (600 mg
three times daily) and subsequently started on chloroquine
300 mg once weekly, which she took for a month. She devel-
oped hemolytic anemia 2 months after stopping chloroquine
(after further travel to Sierra Leone), but blood films and
PCR were negative for malaria. Chloroquine was restarted but
changed to proguanil 100 mg once daily (OD) after 3 weeks. Her
splenomegaly and anemia completely resolved within 2 months.
Summary assessment. Chronic malaria with HMSS and
hemolysis; possible reinfection.
Case 2. A 61-year-old woman from Sierra Leone, who had
arrived in the United Kingdom 6 months before, was referred
with abdominal pain. Ultrasound scanning of her abdomen
showed 15 cm splenomegaly and increased periportal liver
echogenicity, suggesting periportal fibrosis. Schistosomal serol-
ogy was positive and ova of Schistosoma mansoni were seen
on stool microscopy. Histologic examination of liver biopsy
showed pipestem fibrosis. A diagnosis of hepatosplenic schis-
tosomiasis was made, and she was treated with praziquantel
20 mg/kg twice.
Five years later, she returned to clinic complaining that her
abdominal pain had never improved and had recently become
more severe. Schistosomal serology was now negative. Blood
film microscopy was negative for malaria but serology was
strongly positive. Review of the initial histology revealed
hemozoin pigment in Kupffer cells. This finding raised the
possibility of chronic malaria, (hemozoin is only occasionally
seen in chronic schistosomiasis). She was commenced on
chloroquine 300 mg weekly and proguanil 100 mg OD. A
repeat ultra sound scan 2 months later confirmed complete
resolution of the splenomegaly.
Summary assessment. Chronic malaria with HMSS undiag-
nosed on initial presentation.
Case 3. A 16-year-old Somalian woman, resident in the
United Kingdom for 6 months, presented with abdominal
pain and fever. Gross splenomegaly was noted on examina-
tion. Malaria serology was strongly positive and IgM raised.
Multiple blood films were negative for malaria, but PCR for
P. falciparum DNA was positive. She was treated with qui-
nine for 1 week and was subsequently given 6 months of
choloroquine (300 mg weekly) and proguanil (200 mg daily),
with complete resolution of her splenomegaly.
Summary assessment. Chronic malaria with HMSS.
Case 4. A 33-year-old Nigerian man presented with lethargy
and abdominal pain. He had not traveled to a malarial area in
the preceding 7 years. Gross splenomegaly was noted on
examination. Malarial serology was positive and serum IgM
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was 7.1 g/L. No malarial parasites were seen on examination
of a blood film but a malarial antigen test (BinaxNow; Alere)
was positive. He was treated with a short course of mefloquine
followed by 6 months of chloroquine and proguanil, after
which his clinical and hematological abnormalities were
resolved. Five years later, his symptoms returned. On this
occasion, his splenomegaly did not respond to antimalarial
therapy. He subsequently died of a widespread anaplastic
malignancy of uncertain origin.
Summary assessment. Chronic malaria with HMSS. Subse-
quent malignancy.
Case 5. A 19-year-old woman from Cote d’Ivoire was
referred for investigation of splenomegaly and pancytopenia.
Malarial serology was positive but serum IgM was not raised.
She was also seropositive for Hepatitis B virus (HBsAg+,
HBe−, anti-HBe+). Microscopy and PCR of whole blood for
malaria species was negative on several occasions. She
received 4 months of weekly chloroquine 300 mg, but her
splenomegaly and cell counts did not improve.
Summary assessment. No evidence of chronic malaria.
Cause of splenomegaly uncertain.
Case 6. A 24-year-old man was referred to a hospital for
investigation of splenomegaly and pancytopenia. He was born
in Sierra Leone and had migrated to the United Kingdom
8 years before. Blood tests on presentation showed anemia,
thrombocytopenia, and leucopenia. Further testing showed
a high antimalarial antibody titer and raised total IgM.
Malaria PCR was negative. After 8 months of treat-
ment with chloroquine, his splenomegaly was unchanged.
He was then prescribed a prolonged course of atovaquone–
proguanil (one tablet OD), with no improvement. He remains
under review.
Summary assessment. No evidence of chronic malaria.
Cause of splenomegaly uncertain.
Case 7. A 30-year-old man, who had recently migrated to
the United Kingdom from Sierra Leone, was referred to a
hospital with abdominal pain. He had experienced febrile
episodes (with occasional jaundice) every 2–3 months for
many years and these had been treated in Sierra Leone with
empirical antibiotics and antimalarial therapy. Examination
showed gross (25 cm) splenomegaly. He was diagnosed with
hepatitis B and D, liver cirrhosis, and schistosomiasis on the
basis of positive serological tests and biopsy.
The degree of splenomegaly was felt to be incompatible
with liver cirrhosis and a diagnosis of HMSS was considered.
Antimalaria antibody titers were found to be strongly posi-
tive and serum IgM was raised. Malaria PCR was negative.
He was treated with proguanil 100 mg daily and chloroquine
250 mg twice weekly for a year, followed by atovaquone–
proguanil for over 3 years, again with no improvement. He
recently re-presented with new onset ascites, likely to be due
to decompensation of his hepatitis B/D–related cirrhosis.
Summary assessment. No evidence of chronic malaria.
Splenomegaly likely related to cirrhosis.
DISCUSSION
This series is the largest described in a non-endemic set-
ting, and the cases illustrate some of the challenges in the
diagnosis and management of such a poorly understood con-
dition. All were treated with prolonged courses of antimalarial
drugs, as they would have been in their countries of origin.
The choice of drug may have been guided by the suggestion
(from the early 1990s) that chloroquine has an immunologi-
cal effect on HMSS in addition to its antimalarial properties.6
Although historical reports have implicated chronic (as
opposed to recurrent) malaria in many cases of HMSS,7,8 the
possibility of subclinical malarial infection was not appreci-
ated in these cases and the diagnosis would have been
impossible because of the lack, until recently, of a sensitive
diagnostic tool.
Four of the seven cases that we reported responded to anti-
malarial therapy. It is notable that each of these individuals
had evidence of active low-grade malarial infection. Those who
failed to respond to the treatment had no detectable malarial
DNA on a validated PCR (PCR sensitivity: 0.01 parasite/μL9
compared with blood film sensitivity at London School of
Hygiene and Tropical Medicine: 5 parasites/μL) (Debbie
Nolder and Peter Chiodini, personal communication). A
variety of drugs were used, and we assume that, where it
was used alone, proguanil was effective due to the low rate
(about 25%) of antifolate resistance in Sierra Leone at this
time.10 These observations confirm what is unprovable in an
endemic malarial area—that, in the absence of reinfection,
elimination of chronic malaria leads to resolution of HMSS.
The diagnostic criteria for HMSS were last amended in
1997, before the advent of molecular tests for malaria. Since
then, studies have confirmed that chronic malaria is strongly
associated with splenomegaly in endemic areas (80% versus
3.5% with no splenomegaly).11 Scattered reports of cases of
HMSS in non-endemic areas have documented successful treat-
ments with short courses of antimalarial therapy, rather than
the prolonged prophylactic courses used in the tropics.12–14
These data, together with our finding of chronic malaria in
those who responded to antimalarials, suggest a role for
PCR in identifying individuals with splenomegaly who will
respond to treatment for HMSS, and we therefore recommend
that this may be added to the diagnostic criteria for HMSS.
The management of cases of splenomegaly that do not
respond to antimalarial therapy represents a particular chal-
lenge. The surgical risks of splenectomy are often considered
to be unacceptable, which leaves these patients at risk of
bleeding and traumatic splenic rupture. The development of
lymphoma also appears to be a significant risk in HMSS.14,15
Unfortunately, it can be impossible to distinguish HMSS
from splenic lymphoma with standard clinical and hemato-
logical techniques.5 In cases where chronic malaria has been
excluded using PCR or after a trial of therapy, and if other
relevant infections such as visceral leishmaniasis and viral
hepatitis have also been excluded, early splenectomy to mini-
mize these risks may be appropriate.
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